Full Press Release Details
TELA Bio Announces U.S. Commercial Launch of
OviTex PRS Long-Term Resorbable for Plastic and Reconstructive Surgery
New addition expands reconstruction options
for surgeons and patients
August 16, 2023 - TELA Bio, Inc. (NASDAQ: TELA), a commercial-stage medical technology company focused
on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration
of the patient's own anatomy, today announced the launch of their OviTex PRS Long-Term Resorbable product. OviTex PRS Long-Term Resorbable
is intended for implantation to reinforce soft tissue where weakness exists in patients requiring soft tissue repair or reinforcement
in plastic and reconstructive surgery. The device is supplied sterile and is intended for one time use.
OviTex PRS Long-Term Resorbable supplements the
Company's existing OviTex PRS portfolio, which includes OviTex PRS Permanent and OviTex PRS Short-Term Resorbable configurations. The
OviTex PRS portfolio is designed to improve outcomes by facilitating functional tissue remodeling while controlling the degree and direction
of stretch. OviTex PRS Long-Term Resorbable enhances the OviTex PRS portfolio with specific design features, including bi-directional
stretch and a fully resorbable, long-term polymer for reinforcement.
"We are excited to offer expanded clinical
utility of the OviTex PRS portfolio to surgeons and patients in plastic and reconstructive surgery," said Antony Koblish, President
and CEO of TELA Bio. "OviTex PRS Long-Term Resorbable is an important addition to the portfolio as it will allow surgeons to address
clinical indications that require longer term reinforcement while avoiding the use of permanent materials."
6,800+ implantations at over 400 healthcare facilities, OviTex PRS is the only biologic reinforced with interwoven polymer sutures
designed specifically for plastic and reconstructive surgery. This next-generation reinforced biologic is purposefully designed for consistency
in stretch, permeability, and handling while facilitating functional remodeling. The OviTex PRS portfolio provides multiple resorption,
stretch, and shape offerings to meet the unique needs of each patient.
"The OviTex PRS portfolio provides surgeons
with an innovative and effective platform for soft-tissue reconstruction," said Dr. Howard Langstein, MD, Professor of Plastic
Surgery University of Rochester Medical Center. "My experience with OviTex PRS has been very positive and the addition of a long-term
resorbable reinforcement option further expands the treatment options for my patients."
visit www.ovitexprs.com .
About TELA Bio, Inc.
TELA Bio, Inc. (NASDAQ: TELA) is a commercial-stage
medical technology company focused on providing innovative technologies that optimize clinical outcomes by prioritizing the preservation
and restoration of the patient's own anatomy. The Company is committed to providing surgeons with advanced, economically effective soft-tissue
reconstruction solutions that leverage the patient's natural healing response while minimizing long-term exposure to permanent synthetic
materials. For more information, visit www.telabio.com.
OviTex PRS Reinforced Tissue Matrix is intended
for implantation to reinforce soft tissue where weakness exists in patients requiring soft tissue repair or reinforcement in plastic
and reconstructive surgery. The device is supplied sterile and is intended for one-time use.
Do not use OviTex PRS in patients with a known
sensitivity to materials of ovine (sheep) origin. For prescription use only. For additional important safety information, please see
the OviTex PRS Instructions for Use.
Caution Regarding Forward-Looking Statements
press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Words such
as "may," "might," "will," "should," "believe," "expect," "anticipate,"
"estimate," "continue," "predict," "forecast," "project," "plan," "intend"
or similar expressions, or statements regarding intent, belief, or current expectations are forward-looking statements and reflect the
current beliefs of TELA's management, including with respect to the launch of the OviTex PRS Long-Term Resorbable product. These statements
are not guarantees of future performance and are subject to certain risks, uncertainties and other factors that could cause actual results
and events to differ materially and adversely from those indicated by such forward-looking statements including, among others
the impact to our business from macroeconomic conditions, including the ongoing response to the COVID-19 pandemic, recessionary concerns,
banking instability, and inflationary pressures, potentially impacting our ability to market our products, demand for our products due
to the deferral of elective procedures, the labor and staffing environment in the healthcare industry, disruption in our supply chain,
or pricing pressures concerning our products or the procedures using our products; our ability to achieve or sustain profitability; our
ability to gain market acceptance for our products and to accurately forecast and meet customer demand; our ability to compete successfully;
that data from earlier studies related to our products and interim data from ongoing studies may not be replicated in later studies or
indicative of future data; that data obtained from clinical studies using our product may not be indicative of outcomes in other surgical
settings; our ability to enhance our product offerings; development and manufacturing problems; capacity constraints or delays in production
of our products; maintenance of coverage and adequate reimbursement for procedures using our products; product defects or failures.
These and other risks and uncertainties are described more fully in the "Risk Factors" section and elsewhere in our filings
with the Securities and Exchange Commission and available at www.sec.gov, including in our Annual Report on Form 10-K and Quarterly
Reports on Form 10-Q. Any forward-looking statements that we make in this announcement speak only as of the date of this press release,
and TELA assumes no obligation to update forward-looking statements whether as a result of new information, future events or otherwise
after the date of this press release, except as required under applicable law.